Last updated: July 16, 2026
Vifor v. Mylan (3:19-cv-13955): Litigation Summary, Patent Issues, and Generic Entry Risk for VELPHORO (sucroferric oxyhydroxide)
VIFOR (INTERNATIONAL) AG sued Mylan Laboratories Ltd. in the U.S. District Court for the District of New Jersey under Hatch-Waxman in case 3:19-cv-13955. The dispute centers on patents listed in the Orange Book for VELPHORO (sucroferric oxyhydroxide tablets) and alleges Mylan’s ANDA would infringe those asserted patents. The litigation posture and the practical entry timeline are driven by (i) which specific patents were asserted (drug substance, formulation, and/or method-of-use) and (ii) whether the case ended in an adjudicated merits decision or a settlement triggering market-entry conditions.
What patent claims were at issue in VIFOR (INTERNATIONAL) AG v. MYLAN (3:19-cv-13955)?
Which Orange Book patents did Vifor assert?
Hatch-Waxman complaints typically assert infringement of Orange Book-listed patents tied to the reference listed drug (RLD). In this case, Vifor’s asserted claims would map to one or more of the following patent clusters for VELPHORO:
- Drug substance patents (sucroferric oxyhydroxide composition and/or preparation)
- Formulation or solid-state patents (tablet composition, particle properties, granulation)
- Method-of-use patents (indications and dosing regimens for hyperphosphatemia in CKD)
How do infringement theories usually break down in VELPHORO cases?
For sucroferric oxyhydroxide tablets, infringement arguments typically focus on whether the accused ANDA product:
- matches the claimed ferric oxyhydroxide-sucrose core and associated stoichiometry/structural limitations,
- uses a protected manufacturing process or creates the claimed particle/aggregate characteristics, and
- satisfies any formulation limitations that influence bioavailability and phosphate binding.
What happened procedurally in case 3:19-cv-13955 (motions, rulings, stay status)?
Case progression most relevant to generic launch
For Paragraph IV-based ANDA litigation, business impact hinges on:
- whether the court entered a temporary restraining order / preliminary injunction,
- whether the action was stayed under 30-month stay mechanics (or related procedural posture),
- whether the asserted patents were ruled invalid/enjoined/not infringed at an early stage, or
- whether the case resolved via settlement and consent judgment.
Procedural outcomes that change the market timeline
Key markers that determine when Mylan could launch include:
- final judgment on infringement/validity for each asserted patent, or
- settlement terms that specify:
- launch date,
- carve-outs for non-infringing SKUs or strengths,
- labeling commitments,
- payment structure,
- stipulated injunction and/or dismissal without prejudice.
Did the case reach a merits decision or end in settlement?
Why resolution type matters
- A final merits decision creates a clearer FDA and market pathway for Mylan and other ANDA filers.
- A settlement often replaces uncertainty with contractually agreed entry dates but may involve carve-outs and post-landing enforcement.
What you should expect to drive the outcome in this fact pattern
In VELPHORO litigation involving sucroferric oxyhydroxide, the usual resolution drivers are:
- claim construction disputes for formulation/process limitations,
- validity challenges tied to prior art around sucrose-based ferric oxyhydroxide carriers,
- enforceability challenges for late-filed or continuation-heavy claims.
What is the Orange Book status of VELPHORO (sucroferric oxyhydroxide) and how does it map to this lawsuit?
Orange Book listing logic
The Orange Book controls what is eligible for Hatch-Waxman infringement assertions. In this litigation, the “patent listing” step is the anchor for:
- the selection of asserted patents,
- the trigger for Paragraph IV notice,
- the availability of the 30-month stay.
How to interpret “Orange Book coverage” for VELPHORO tablet generics
Coverage often includes:
- at least one drug substance or composition patent, and
- at least one formulation/process patent, depending on the specific RLD patent package at the time of the ANDA.
What patent expiration dates and exclusivity timelines drive the VELPHORO competitive calendar?
How to use expiration windows to forecast launch risk
In sucroferric oxyhydroxide tablet disputes, launch windows usually depend on the last-to-expire of:
- the last asserted Orange Book patent adjudicated or settled,
- any patent term adjustments, and
- any additional exclusivity that may attach to the RLD (if applicable).
Practical effect of multiple asserted patents
Where multiple patents are asserted, a generic launch typically requires either:
- all asserted patents fall (invalidation and/or non-infringement), or
- settlement grants a carve-out or allows launch by a date.
Which Paragraph IV challenges were made by Mylan in 3:19-cv-13955?
Typical Paragraph IV defenses for sucroferric oxyhydroxide
Paragraph IV cases usually bundle defenses into:
- Non-infringement: the ANDA product does not meet claim limitations.
- Invalidity: anticipation, obviousness, written description/enablement.
- Procedural defenses: standing, failure to comply with notice requirements, or pleading sufficiency.
Business read-through
- If the plaintiff targets formulation/process claims, the invalidity case often turns on prior art manufacturing records and physicochemical characterization evidence.
- If the asserted patents are method-of-use, the dispute often hinges on labeling and patient population carve-outs.
How strong is the patent estate behind VELPHORO tablets in this litigation?
What determines enforceability strength in this category
For ferric oxyhydroxide-sucrose complexes, patent strength in litigation often depends on:
- whether the claims are narrow enough to avoid prior art,
- whether enablement and written description support the scope,
- whether the accused product can be characterized precisely to prove or disprove structural limitations.
Litigation posture as an indicator
The procedural outcome pattern (motions to dismiss, claim construction, summary judgment, trial) is typically the strongest real-world signal of case strength, but this analysis requires the docket’s actual filings and rulings in 3:19-cv-13955.
What settlement terms or consent judgment terms typically appear in VELPHORO ANDA cases?
Common settlement components
In Orange Book litigations for tablet generics, settlements frequently include:
- stipulated launch dates for generic product introduction,
- agreed design-around boundaries,
- limitations on labeling or promotion to reduce method-of-use exposure,
- dismissal terms and ongoing cooperation on FDA processes.
How to interpret settlement impact
Even with settlement, enforcement risk persists if:
- the generic product formulation drifts outside agreed design-arounds,
- labeling deviates,
- manufacturing changes affect claimed particle properties or process parameters.
What generic entry risks exist for Mylan after 3:19-cv-13955?
FDA and market entry
Even after patent resolution, entry requires:
- FDA approval under the ANDA,
- post-approval compliance with manufacturing controls and specs, and
- consistent labeling aligned with the allowed non-infringing scope.
Repeat-risk from future filings
If the litigation resolved only specific patents or specific formulations:
- future ANDA applicants may still face separate infringement theories,
- newly granted patents or continuation claims could add enforcement exposure depending on timing.
How does Mylan’s position in this case compare with other VELPHORO ANDA filers?
Competitive dynamics
VELPHORO generics face a limited set of pathways:
- design-around of formulation/process constraints,
- challenge packages against the strongest patents in the Orange Book,
- reliance on settlement windows to avoid losing at trial.
What this means commercially
If Mylan negotiated settlement or obtained a favorable ruling on the last-to-expire asserted patent, other filers may accelerate launch planning against the same patent package.
What litigation affects investors and licensing partners: key dates and decision points?
Decision points that determine valuation impact
For each asserted patent, the following milestones dominate risk:
- complaint filing date and asserted patent set,
- Paragraph IV notice date and 30-month stay calculation,
- any claim construction ruling dates,
- summary judgment or dismissal dates,
- settlement or consent judgment execution and dismissal entries.
Key takeaway for licensing
If the case settled, the settlement agreement becomes the practical license boundary:
- permitted launch timing,
- enforcement carve-outs,
- and any constraints on formulation changes.
Key Takeaways
- VIFOR (INTERNATIONAL) AG v. Mylan Laboratories Ltd. (3:19-cv-13955) is a U.S. Hatch-Waxman patent infringement case tied to Orange Book-listed patents for VELPHORO (sucroferric oxyhydroxide).
- The litigation’s commercial import turns on the specific asserted Orange Book patents, whether the outcome was merits adjudication or settlement, and any consent-judgment or agreement terms controlling launch.
- Generic entry for Mylan is determined by the last-to-expire and last-to-fail (or settled) patent coverage package, plus FDA approval and post-approval product compliance.
FAQs
- Which VELPHORO Orange Book patents were asserted against Mylan in 3:19-cv-13955?
- What is the 30-month stay status for Mylan’s ANDA in this case’s procedural posture?
- Did the court construe any claims in 3:19-cv-13955 in a way that narrowed infringement?
- If the case settled, what launch date or labeling/design constraints were typically imposed?
- Do any later-granted patents or continuations for VELPHORO extend enforcement beyond this case?
References (APA)
- VIFOR (INTERNATIONAL) AG v. Mylan Laboratories Ltd., No. 3:19-cv-13955, U.S. District Court for the District of New Jersey (docket and filings).
